Replimune Group Stock Soars 85.33% Amid Lawsuit Reassessment

On July 30, 2025, Replimune Group's stock surged by 85.33% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

The recent surge in Replimune Group's stock price can be attributed to several key developments. Notably, a class action lawsuit has been filed against the company, alleging that Replimune misled investors regarding the viability of its IGNYTE trial. The lawsuit claims that the company overstated the prospects of the trial, leading to a complete response letter from the FDA, which deemed the trial inadequate and not well-controlled. This news caused a significant drop in the stock price on July 22, 2025, but the recent pre-market surge suggests that investors may be reassessing the company's prospects.

Investors who purchased Replimune Group securities between November 22, 2024, and July 21, 2025, are eligible to participate in the class action lawsuit. The lead plaintiff deadline is September 22, 2025, and shareholders who wish to serve as lead plaintiff must file their papers with the court by this date. The lawsuit aims to hold the company accountable for its alleged misrepresentations and to recover losses for affected investors.